Jonathan Baell Explained

Jonathan Baell (né Ball) is trained as an Australian medicinal chemist and is currently executive director, early leads chemistry at Lyterian Therapeutics in San Francisco. Prior to this, he was a research professor in medicinal chemistry at the Monash Institute of Pharmaceutical Sciences (MIPS),[1] the director of the Australian Translational Medicinal Chemistry Facility[2] and a Chief Investigator at the ARC Centre for Fragment-Based Design.[3] He was President of the International Chemical Biology Society 2018-2021 and is currently chair of the board.[4] His research focuses on the early stages of drug discovery, including high-throughput screening (HTS) library design, hit-to-lead and lead optimization for the treatment of a variety of diseases, such as malaria and neglected diseases.[5]

Early life and education

Baell was born in Tanzania, East Africa in 1965. He migrated with his family to Tasmania, Australia in 1977. Baell completed a Bachelor of Science with Honours from the University of Tasmania in 1986.[6] He then moved to Melbourne to undertake a PhD project with Professor Peter Andrews and Professor Paul Alewood at the Monash University Faculty of Pharmacy and Pharmaceutical Sciences (previously known as the Victorian College of Pharmacy), graduating in 1992.[7]

Career

At the completion of his PhD, Baell commenced his postdoctoral research at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), quickly rising to the rank of senior research scientist at the age of 28.[8]

In 2001, Baell moved to the Walter and Eliza Hall Institute (WEHI), where he served as the Head of Medicinal Chemistry for the subsequent decade. During this time, Baell published a paper in the Journal of Medicinal Chemistry describing a naturally occurring chemical derived from Ammi visnaga, khellinone, as the basis of a potential new class of immunosuppressive drugs for the treatment of multiple sclerosis.[9] This area of research won him the Biota Award for Medicinal Chemistry from the Royal Australian Chemical Institute (RACI) in 2004.[10] [11]

After 10 years at WEHI, Baell moved his research lab to MIPS, where he was appointed as a research professor in 2012.

Baell coined the term PAINS (pan-assay interference compounds) to describe chemical compounds that are often picked up as false positive hits from HTS campaigns.[12] His 2010 publication identified the chemical structures of these compounds and constructed electronic filters that can be used in HTS campaigns to remove PAINS from screening hits. The implications of PAINS in the drug discovery pipeline resulted in the American Chemical Society to include the removal of PAINS from screening hits as a publication requirement for its journals in 2017.[13] The impact of Baell's work on PAINS was recognized in 2020 when he was presented the Scientific Achievement Award in Drug Discovery and Development by the American Society for Pharmacology and Experimental Therapeutics.[14]

In 2018, Baell was awarded the Adrien Albert Award by RACI.[15] It is the most prestigious award for RACI Medicinal Chemistry & Chemical Biology Division, given for exceptional research in the field of medicinal chemistry, agricultural chemistry or chemical biology.[16]

Other appointments

Awards and honors

2004 - Biota Award for Medicinal Chemistry, RACI

2018 - Adrien Albert Award, RACI

2019 - Faculty Research Award, Monash University Faculty of Pharmacy and Pharmaceutical Sciences[28]

2020 - Scientific Achievement Award in Drug Discovery and Development, ASPET

Patents

According to the Espacenet database, Baell has registered 49 patents[29] as of July 2020.

External links

Notes and References

  1. Web site: Jonathan Baell. 2020-07-28. Monash University. en.
  2. Web site: Our Team and Contacts. 2020-07-28. Australian Translational Medicinal Chemistry Facility. en.
  3. Web site: 2020-04-16. Chief Investigators. 2020-07-28. ARC Centre for Fragment-Based Design. en-GB.
  4. Web site: ICBS Leadership - International Chemical Biology Society. 2020-07-28. www.chemical-biology.org.
  5. Web site: 2013-10-07. Prof. Jonathan Baell of "PAINS" Filters Fame from Monash University. 2020-07-28. Collaborative Drug Discovery Inc. (CDD). en-US.
  6. Ball . Jonathan Bayldon . Synthesis and reactions of some benz[a]indoloquinolizines . 1986 . 225117022 .
  7. Napper . AD . Interview with Jonathan Baell, PhD . ASSAY and Drug Development Technologies . April 2016 . 14 . 3 . 164–167 . 10.1089/adt.2016.29035.jba . 27078678 .
  8. Web site: Baell, Jonathan. 2020-07-28. American Chemical Society. en.
  9. Baell . Jonathan B. . Gable . Robert W. . Harvey . Andrew J. . Toovey . Nathan . Herzog . Tanja . Hänsel . Wolfram . Wulff . Heike . Khellinone Derivatives as Blockers of the Voltage-Gated Potassium Channel Kv1.3: Synthesis and Immunosuppressive Activity . Journal of Medicinal Chemistry . April 2004 . 47 . 9 . 2326–2336 . 10.1021/jm030523s . 15084131 .
  10. Web site: The Royal Australian Chemical Institute. dead. https://web.archive.org/web/20170707204208/https://www.raci.org.au/document/item/1381. 2017-07-07. 2020-07-28. RACI.
  11. Web site: Jonathan Baell wins Biota Award for Medicinal Chemistry. 2020-07-28. EurekAlert!. en.
  12. Baell . Jonathan B. . Holloway . Georgina A. . New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays . Journal of Medicinal Chemistry . April 2010 . 53 . 7 . 2719–2740 . 10.1021/jm901137j . 20131845 . 10.1.1.394.9155 .
  13. Aldrich . Courtney . Bertozzi . Carolyn . Georg . Gunda I. . Kiessling . Laura . Lindsley . Craig . Liotta . Dennis . Merz . Kenneth M. . Schepartz . Alanna . Wang . Shaomeng . The Ecstasy and Agony of Assay Interference Compounds . ACS Central Science . March 2017 . 3 . 3 . 143–147 . 10.1021/acscentsci.7b00069 . 28386587 . 5364449 .
  14. Web site: 2020 Award Winners. 2020-07-28. ASPET. en.
  15. Web site: MIPS researcher awarded Adrien Albert Award by RACI. 2020-07-28. Faculty of Pharmacy and Pharmaceutical Sciences. en.
  16. Web site: Medicinal Chemistry & Chemical Biology Division. 2020-07-28. www.raci.org.au. en.
  17. Web site: Strategic Advisory Board. 2020-07-28. www.griffith.edu.au. en.
  18. Web site: Scientific Advisory Team – Novick Biosciences. 2020-07-28. en-US.
  19. Web site: Management Team and Scientific Advisory Board. 2020-07-28. Regen BioPharma, Inc.. en.
  20. Web site: TopoGEN Scientific Advisory Board. 2020-07-28. www.topogen.com. en-gb.
  21. Medicine. SEngine Precision. 2019-04-25. SEngine Precision Medicine Announces Renowned Medicinal Chemist to Join Scientific Advisory Board. 2020-07-28. GlobeNewswire News Room.
  22. Web site: Future Medicinal Chemistry - Editorial Advisory Board. 2020-07-28. www.future-science.com.
  23. Issue Editorial Masthead . Journal of Medicinal Chemistry . July 2020 . 63 . 14 . jmv063i014_1397242 . 10.1021/jmv063i014_1397242 . free .
  24. Web site: Methods and Protocols. 2020-07-28. www.mdpi.com. en.
  25. Web site: Biology. 2020-07-28. www.mdpi.com. en.
  26. Web site: Current Medicinal Chemistry. 2020-07-28. Current Medicinal Chemistry.
  27. Web site: Committee Details. 2020-07-28. IUPAC International Union of Pure and Applied Chemistry. en-US.
  28. Web site: The Faculty Research Award. 2020-07-28. Faculty of Pharmacy and Pharmaceutical Sciences. en.
  29. Web site: Espacenet – search results. 2020-07-28. worldwide.espacenet.com.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Jonathan Baell".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.